Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

Dr. Beer, Professor of Medicine, Oregon Health Sciences University, describes the use of DNA repair markers when determining treatment of prostate cancer patients

Tags: ASCO GI Conference CoverageProstate

Published: 16 February 2020

Recent Videos: ASCO GI Conference Coverage

video

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

Dr. Beer, Professor of Medicine, Oregon Health Sciences University, describes the use of DNA repair markers when determining treatment of ...

video

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, regarding the results of the TAPUR study presented at ASCO ...

video

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, determines whether to automatically test for the BRAF mutation in ...

video

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, shares how the recent clinical studies concerning "sided-ness" affects the ...

video

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, provided perspective on the combination of regorafenib and checkpoint inhibitors ...

video

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, elaborates on the influence of cell free DNA when making ...

video

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, offers opinion regarding checkpoint inhibitors being used in ...

video

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, discusses quality of life analysis in the IMBRAVE ...

video

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

Crystal Denlinger, MD, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, regarding cell free DNA tests and how ...

video

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, comments on the use of fitness trackers to ...

Related Videos

video-image

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

video-image

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

video-image

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

video-image

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

video-image

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

video-image

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

video-image

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

video-image

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

video-image

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

video-image

David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020

video-image

David H Ilson, MD, on the JAVELIN 100 study and the need for quick responses and immunotherapy in GE

video-image

Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy

video-image

Zev Wainberg, MD, explains appropriate therapy following initial treatment for GI & GE tumors

video-image

Zev Wainberg, MD, shares the best way to combine checkpoint inhibitors in gastric and GE tumors

video-image

Zev Wainberg, MD, on the line of therapy for checkpoint inhibitors in gastric and GI cancers

video-image

Hani Babiker, MD, on tumor treatment field combinations in the management of GI malignancies

video-image

Hani Babiker, MD, defines tumor treatment fields as well as the mechanism of action

video-image

Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment

video-image

Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC

video-image

Ahmed Kaseb, MD, shares the role of checkpoint inhibitors when alone and combined with anti-CTLA4

video-image

Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA

video-image

Irvin Modlin, MD, describes whether NETest replaces or supplements imaging

video-image

Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive

video-image

Irvin Modlin, MD, explains the specificity and sensitivity of the NETest

video-image

Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results

video-image

Nevena Damjanov, MD, shares personal opinion of treatment of patient with a high expression of AFP

video-image

Eileen O'Reilly, MD, shares outcomes of the POLO study and its importance to physicians

video-image

Eileen O'Reilly, MD, describes how physicians should test for BRCA in pancreatic cancer patients

video-image

Sam Klempner, MD, describes the role of Cyramza in the treatment of GR junction cancers

video-image

Sam Klempner, MD, considers promising approaches to therapy in development for upper GI malignancies

video-image

Manish Shah, MD, discusses avelumab's effectiveness based on results from the JAVELIN 100 study

video-image

Manish Shah, MD, explains whether levatinib can be combined with I-O to treat and manage GI cancer

video-image

Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients

video-image

Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility

video-image

Daniel Catenacci, MD, on the role of margetuximab to improve treatment outcomes of GI cancers

video-image

Daniel Catenacci, MD, shares opinion on the role of checkpoint inhibitors for GI malignancies

video-image

Philip Philip, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Philip Philip, MD, shares opinion on treatment of a BRCA+ pancreatic cancer patient

video-image

Philip Philip, MD, explains how physicians should test for BRCA in pancreatic cancer patients

video-image

Philip Philip, MD, on the outcomes of the POLO study and its importance to physicians

video-image

Daneng Li, MD, regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for HCC

video-image

Daneng Li, MD, shares latest thoughts on checkpoint inhibitors being combines with TKIs

video-image

Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment

video-image

Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time

video-image

Ryan Corcoran, explains cell free DNA and ways to test for it

video-image

Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma

video-image

Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC

video-image

Richard Kim, MD, on the combination of cabozantinib and checkpoint inhibitors to improve HCC outcomes

video-image

Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment

video-image

Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies

video-image

Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC

video-image

Philip Philip, MD, provides thoughts on the role of PARP inhibitors in advanced pancreatic cancer

video-image

Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age

video-image

Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients

video-image

David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients

video-image

David H Ilson, MD, shares results of the ARTDECO study and it's importance to physicians

video-image

Zev Wainberg, MD, shares results of study regarding gastric and GE cancers presented at ASCO GI

video-image

Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA

video-image

Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard

video-image

Daneng Li, MD, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes

video-image

Richard Kim, MD determines whether checkpoint inhibitors combine with regorafenib for HCC treatment

video-image

Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study

video-image

Hani Babiker, MD, elaborates on tumor treatment fields applying to GI malignancies

video-image

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

video-image

Ahmed Kaseb, MD, on combining cabozantinib with checkpoint inhibitors for treatment of HCC

video-image

Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study

video-image

Nevena Damjanov, MD, on impressions of the study combining cabozantinib with checkpoint inhibitors in advanced HCC patients

video-image

Nevena Damjanov, MD, elaborates on the role of TKIs in managing 2nd line HCC patients

video-image

Nevena Damjanov, MD, explains the outcomes of combining atezolizumab with bevacizumab in 1st line HCC patients

video-image

Eileen O'Reilly, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Eileen O'Reilly, MD, provides evidence to inform treatment of pancreatic cancer patients

video-image

Manish Shah, MD, regarding the use of liquid biopsy to diagnose and treat GI cancers

video-image

Manish Shah, MD, on the role of Cyramza in the treatment of gastric and esophageal cancers

video-image

Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancer

video-image

Daniel Catenacci, MD, elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

video-image

John Strickler, MD, shares thoughts on molecular subtyping of pancreatic cancer

video-image

John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC

video-image

John Strickler, MD, regarding pembrolizumab vs. chemotherapy in 2nd line advanced esophageal cancer

video-image

John Strickler, MD, on combo pembrolizumab, trastuzumab, capecitabine & oxaliplatin in mEGA

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

video-image

Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC

video-image

Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer

video-image

Raymond Wadlow, MD, on the outcomes of Keynote 181 in esophageal cancer

video-image

Bassel El-Reyes, MD, speculates on promising novel therapies being developed for pancreatic cancer

video-image

Bassel El-Reyes, MD, considers upfront surgery for resectable pancreatic cancer

video-image

Martine Extermann, MD, PhD, on identifying the right treatment for patients with gastric cancer

video-image

Bassel El-Reyes, MD, offers his opinion on NGS & BRCA gene testing for pancreatic cancer

video-image

Martine Extermann, MD, PhD, shares the results of the FOLFOX +/- andecaliximab study from GI '19

video-image

Bassel El-Reyes, MD, regarding molecular subtyping of pancreatic cancer

video-image

Martine Extermann, MD, PhD, on the investigation of TAS-102 in metastatic gastric cancer

video-image

Bassel El-Reyes, MD, on screening patients at high risk for pancreatic cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

video-image

Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

video-image

Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma

video-image

Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma

video-image

Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

video-image

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

video-image

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

video-image

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

video-image

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

video-image

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

video-image

Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

video-image

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC

video-image

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

video-image

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

video-image

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

video-image

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

video-image

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

video-image

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

video-image

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

video-image

Howard Hochster, MD, regarding the role of genetic testing in mCRC

video-image

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC

video-image

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

video-image

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

video-image

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

video-image

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

video-image

Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018

video-image

Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials

video-image

Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board

video-image

Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018

video-image

Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC

video-image

Philip Philip, MD, PhD, FRCP, on the implications of the LAPACT study presented at ASCO 2018

video-image

Philip Philip, MD, PhD, FRCP, considers the impact of immunotherapy agents in pancreatic cancer

video-image

Philip Philip, MD, PhD, FRCP, regarding key unmet needs in pancreatic ductal adenocarcinoma

video-image

Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018

video-image

Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib

video-image

Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients

video-image

David Ilson, MD, PhD, considers how to assess response in gastroesophageal cancer patients

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

video-image

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

video-image

Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC

video-image

Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients

video-image

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

video-image

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

video-image

Richard Kim, MD, offers analysis of the RAINFALL study in metastatic gastric & GE junction cancer

video-image

Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management

video-image

Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients

video-image

Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)

video-image

David Ilson, MD, PhD, discusses what can be done to improve outcomes in esophageal adenocarcinoma

video-image

David Ilson, MD, PhD, examines the results of the RAINFALL study at ASCO GI 2018

video-image

David Ilson, MD, PhD, on strategies for managing gastroesophageal patients after neoadjuvant therapy

video-image

David Ilson, MD, PhD, on how we can individualize treatment of gastroesophageal cancer patients

video-image

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

video-image

Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib

video-image

Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today

video-image

Laura Dawson, MD, FRCPC, on additional randomized studies of external beam radiation

video-image

Laura Dawson, MD, FRCPC, tells us about the results of the START study

video-image

Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC

video-image

Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)

video-image

Alan Venook, MD, outlines the role of liquid biopsy in gastrointestinal cancers

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients

video-image

Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Alan Venook, MD, explains how tumor sidedness affects therapeutic choice

video-image

Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer

video-image

Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer

video-image

Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer

video-image

Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy

video-image

Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

video-image

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

video-image

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

video-image

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

video-image

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

video-image

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

video-image

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

video-image

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

video-image

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

video-image

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

video-image

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

video-image

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

video-image

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

video-image

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

video-image

Johanna Bendell, MD, discusses the RESORCE trial data

video-image

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

video-image

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

video-image

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

video-image

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment

video-image

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

video-image

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

video-image

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

video-image

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

video-image

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

video-image

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research

video-image

Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016

video-image

TAS-102 versus 5-flourouracil and other more familiar agents ASCO GI 2016

video-image

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

video-image

RECOURSE trial did performance status impact benefit from TAS-102 at ASCO GI 2016

video-image

Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

video-image

Design of the RECOURSE trial on which the FDA approved TAS-102

video-image

RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC

video-image

Biggest questions facing the treatment of colorectal cancer ASCO GI 2016

video-image

How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016

video-image

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

video-image

Potential cases to use Regorafenib over TAS-102 ASCO GI 2016

video-image

Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016

video-image

More money should be allocated to early detection and screening in colorectal cancer ASCO GI 2016

video-image

PD-L1 markers in MMR deficient cancers ASCO GI 2016

video-image

Mismatch Repair (MMR) deficient and the use of PD-1 blockade ASCO GI 2016

video-image

ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016

video-image

Planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers ASCO Gi 2016

video-image

STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016

video-image

RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016

video-image

Does the Asian population differ from the western populations in regards to gastric cancers

video-image

The future of gastric cancers will be targeted agents including immunotherapy

video-image

FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma

video-image

Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma

video-image

ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer

video-image

Managing patients on regorafenib including adverse events

video-image

Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies

video-image

KEYNOTE-028 results with pembrolizumab

video-image

Pembrolizumab looks promising according to KEYNOTE-028 results

video-image

Immunotherapy Shows Promise in MSI-High Colorectal Cancer

video-image

Pancreatic Cancer News from ASCO GI 2016

video-image

Weekly T-DM1 surprising or disappointing ASCO GI 2016

video-image

GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

video-image

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016

video-image

Post-operative adjuvant therapy for resectable patients with node positive oesophageal cancer ASCO GI 2016

video-image

FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016

video-image

Future of TAS-102 and regorafenib for patients with colorectal cancer

video-image

TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1

video-image

RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib

video-image

Importance of performance status prior to starting regorafenib at ASCO GI 2016

video-image

Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

video-image

Scott Tagawa, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

video-image

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

video-image

Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC

video-image

Tanya Dorff, MD, shares thoughts of the optimal sequence of atezolizumab and sip-T in mCRPC

video-image

Oliver Sartor, MD, on the exciting recent outcomes investigating Lu-177–PSMA in patients with advanced prostate cancer

video-image

Lucia Nappi, MD, explains micro RNA usage to aid in the diagnosis and treatment of testicular cancer

video-image

Anis Hamid, describes how RNA profiling guides treatment decisions about chemotherapy for metastatic prostate cancer

video-image

Anis Hamid, MD, describes real world impact of immunotherapy when added to oral therapies for advanced prostate cancer

video-image

Daniel P. Petrylak, MD, explains the effect of second antigen spread in metastatic castration resistant prostate cancer patients

video-image

Daniel P. Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in metastatic castration resistant prostate cancer

video-image

Landon Brown, MD, shares real world evidence regarding immunotherapy, RCC, and brain metastasis

video-image

Bradley McGregor, MD, shares presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, elaborates on presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, regarding recent outcomes investigating 225Ac-PSMA-617 in patients with advanced prostate cancer

video-image

Landon Brown, MD, defines CTC chromosomal instability and neuroendocrine phenotype

video-image

Rana McKay, MD, elaborates on presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Andrew Armstrong, MD, provides insight as to genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Andrew Armstrong, MD, shares updates on the ARCHES study investigating enzalutamide in metastatic prostate cancer patients

video-image

Andrew Armstrong, MD, on determining treatment of prostate cancer with DNA repair markers

video-image

Tom Beer, MD, explains whether PFS2 is a legitimate endpoint in prostate cancer clinical trials

video-image

Tom Beer, MD, shares impressions of the TITAN study invesigating 1st line therapy in mCRPC patients

video-image

Jeanny Aragon-Ching, MD, summarize the EV103 study investigating enfortumab + pembrolizumab

video-image

Jeanny Aragon-Ching, MD, explains efficacy and toxicities differences as they are used in NM-CRPC

video-image

Jeanny Aragon-Ching, MD, discusses STOMP trial data regarding surveillance vs directed therapy

video-image

Daniel P. Petrylak, MD, on the integration of liquid biopsy being targeted into the treatment of prostate cancer

video-image

Daniel P. Petrylak, MD, on the current role of circulating tumor cell components via liquid biopsy prostate cancer treatment

video-image

Oliver Sartor, MD, on future use of liquid biopsy into the treatment of prostate cancer

video-image

Tanya Dorff, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Oliver Sartor, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Anis Hamid, MD, on impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Rana McKay, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Andrew Armstrong, MD, shares impressions of the CARD study investigating cabazitaxel in metastatic castration-resistant prostate cancer patients

video-image

Tom Beer, MD, shares impressions of the CARD study investigating cabazitaxel in mCRPC patients

video-image

Jeanny Aragon-Ching, on the impact of the genomic classifier testing when choosing patients with mPC

video-image

Rana McKay, MD, on the real world impact of immunotherapy when added to oral therapies for APC

video-image

Andrew Armstrong, MD, explains whether ARV-7 is predictive of response to taxanes in metastatic prostate cancer patients

video-image

Tanya Dorff, MD, elaborates on data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, shares data of cellular immunotherapy within the African American population

video-image

Anis Hamid, MD, describes quality of life analysis' impact treatment of metastatic prostate cancer

video-image

Landon Brown, MD, on abiraterone or enzalutamider treatment relating chromosomal instability

video-image

Jeanny Aragon-Ching, MD, on next generation imaging and its impact on prostate cancer treatment

video-image

Daniel P. Petrylak, MD shares his thoughts on the CARD prostate cancer study presented at ASCO GU 2020

video-image

Tom Beer, MD on the data presented at ASCO GU20 investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

video-image

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

video-image

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

video-image

Tomasz M. Beer MD, FACP, considers the role of metformin in castrate-resistant prostate cancer

video-image

Tomasz M. Beer MD, FACP, on the efficacy of abiraterone + enzalutamide in mCRPC

video-image

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

video-image

Nancy A. Dawson, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Tomasz M. Beer MD, FACP, tells us about the ENZAMET study in mHSPC

video-image

Nancy A. Dawson, MD, regarding the ENZAMET study in mHSPC presented at ASCO '19

video-image

William Oh, MD, tells us about the results of Keynote-365 in mCRPC

video-image

William Oh, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

William Oh, MD, considers the role of biomarker selection trials in prostate cancer

video-image

William Oh, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

video-image

Kim Chi, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Kim Chi, MD, provides perspective on biomarker selection trials in prostate cancer

video-image

Kim Chi, MD, regarding the TITAN study presented at ASCO 2019

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC

video-image

Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC

video-image

Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

video-image

Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study

video-image

Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer

video-image

Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019

video-image

Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer

video-image

Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Mark T. Fleming, MD, regarding the Aramis study in prostate cancer

video-image

Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi

video-image

Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

video-image

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer ASCO GU 2016

video-image

Using new therapies earlier in prostate cancer may returns better results

video-image

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer